Inclusion criteria | 1. Age between 40 and 75 years 2. HbA1c between 6.5 and 9.5% 3. Documented known diabetes mellitus type 2 under continuous fixed-dose anti-diabetic treatment for at least 3 months prior to the randomization 4. Documented known coronary artery disease established by coronary angiography under continuous fixed-dose of anti-ischemic treatment for at least 3 months prior to the randomization 5. BMI less than 40 kg/m2 6. Fixed diet and physical activity 7. eGFR greater than 45 ml/min/1.73m2 8. Informed consent given in written form 9. Resting heart rate between 60 to 100 b/min |
Exclusion criteria | 1. Pregnancy 2. Heart Failure (NYHA class 3–4) 3. Left ventricular ejection fraction < 40% 4. Use of anti-coagulant or anti-platelet drugs (except aspirin 80 mg/daily) for at least 3 months prior to the blood sampling 5. Consumption of alcohol, continuous anti-inflammatory drugs (except aspirin 80 mg/daily) or anti-oxidant supplement 6. Use of pioglitazone 7. History of allergic reaction to SGLT2-i medications 8. History of SGLT2-i medication usage 9. Gastrointestinal malabsorption disease 10. History of CABG, ACS, TIA, CVA or PCI during past 3 month 11. History or presence of malignancy 12. Severe HTN Resting systolic blood pressure ≥ 180 mmHg and/or Resting diastolic blood pressure ≥ 120 mmHg 13. Anemia (Hb < 10 g/dl) 14. Platelet count < 100,000/µl 15. History of infection during 1 one month prior to blood sampling 16. History of heart or lung transplant 17. Major psychiatric disorders 18. History of DKA 19. Elevated liver enzymes > 3 times upper normal limit 20. Use of drugs which prolong QT interval 21. Presence of arrhythmia 22. Electrolyte imbalance 23. Patients with pace maker |